Vietnamese experts urged early COPD detection as data presented at a meeting showed 65 to 80 percent of patients are diagnosed only when the disease is severe.
COPD kills more than 25,000 people in Vietnam every year, and roughly two-thirds to four-fifths of patients there are diagnosed only after the disease has become severe.
On November 15, ahead of World COPD Day 2026, the Ho Chi Minh City Association of Asthma, Allergy and Clinical Immunology convened hundreds of respiratory specialists to push a broader model of care — one that reaches patients before their lungs fail, vietnam.vn reported.
The scientific conference, titled Comprehensive COPD Management (BPCO–ACOCU–PFT Day 2026), gathered leading pulmonologists from across the country. Its premise was blunt: treating flare-ups alone is not managing the disease. Vietnam.vn reported that the program aims to update knowledge and practice in COPD care while integrating it with outpatient asthma/COPD management and pulmonary function testing.
Why it matters far beyond one conference hall: the World Health Organization ranks COPD as the third leading cause of death worldwide, and Vietnam carries the highest number of moderate-to-severe cases in the Asia-Pacific region, according to figures cited at the meeting. Experts there describe the disease as a “ticking time bomb” because it worsens silently through exacerbations — acute episodes in which already-narrowed airways become inflamed and breathing deteriorates rapidly.
Associate Professor Dr. Le Thi Tuyet Lan, president of the Ho Chi Minh City Association of Asthma, Allergy and Clinical Immunology, led the gathering of specialists.
The association is now pairing with the pharmacy chain Long Chau, which operates nearly 3,000 pharmacies across 34 provinces and cities staffed by more than 22,000 pharmacists, to carry five core messages about COPD to the public under the banner “Community respiratory care: early screening, proper treatment, healthier living.”
Diagnosis often arrives too late
The central clinical problem the conference targeted is late detection. Between 65 and 80 percent of Vietnamese patients learn they have COPD only once the disease is severe, according to data presented at the meeting. By that stage, the airway remodeling and loss of alveolar surface area — the microscopic sacs where oxygen passes into the blood — cannot be reversed, only slowed.
COPD’s mechanism of action is well understood: long-term exposure to cigarette smoke, biomass fuel smoke or occupational dust triggers chronic inflammation in the bronchi and lung parenchyma. That inflammation narrows airflow permanently, which is why the disease produces its hallmark triad of breathlessness (dyspnea), chronic cough and sputum production.
Spirometry — a simple breathing test measuring how much air a person can force out in one second — can confirm the diagnosis years before symptoms become disabling, yet it remains underused in community settings.
In plain terms: what patients should know
- COPD is a progressive, incurable lung disease, but early diagnosis and inhaled treatment can keep it stable for years.
- A sudden worsening of breathlessness or cough — an exacerbation — is a medical event, not a bad day; it needs prompt attention.
- Correct inhaler technique matters as much as the drug itself; many patients get little benefit because the device is used wrongly.
Two digital tools, with limits
The partnership produced two assessment instruments for home use. CERT helps patients recognize COPD exacerbations — the acute episodes that drive most hospitalizations — while CAAT is a questionnaire for evaluating chronic respiratory disease, allowing patients to track control of their asthma and associated allergies. Both organizations were explicit that neither tool replaces a physician’s diagnosis or assessment.
That caveat is the honest part of the story. Symptom questionnaires can flag deterioration, but they cannot measure lung function; only spirometry performed by a clinician can stage the disease or confirm a new diagnosis. The model being proposed is a relay: pharmacies and patients monitor, physicians confirm and prescribe, and long-term follow-up continues in the community rather than only in hospital during crises.
| Measure | Figure | Source |
|---|---|---|
| Annual COPD deaths in Vietnam | more than 25,000 | WHO, cited at conference |
| Patients diagnosed late (severe stage) | 65–80% | Conference data |
| Long Chau pharmacies / provinces | ~3,000 / 34 | Company, cited by vietnam.vn |
| Pharmacists in network | more than 22,000 | Company, cited by vietnam.vn |
What comes next, and the regional stage
From December 4 to 6, 2026, Long Chau and the Ho Chi Minh City association will join the APAAACI 2026 conference — the largest annual international scientific meeting of the Asia-Pacific region for allergy, asthma and immunology — hosted in Vietnam for the first time. Thousands of regional specialists are expected around the theme of sustainable lifelong care in asthma, allergy and clinical immunology, and Vietnamese representatives will present their community respiratory care experience.
For readers comparing health systems, the pattern is familiar. In the United States, the CDC tracks COPD as a leading cause of death and supports smoking-cessation programs; in the United Kingdom, the NHS runs community spirometry and pulmonary rehabilitation pathways; European regulators through the EMA approve the inhaled corticosteroids, long-acting bronchodilators and combination devices that form the pharmacological backbone of COPD care.
Vietnam’s challenge is structural rather than pharmaceutical: the drugs exist, but the diagnostic pathway — from village pharmacy to spirometer to pulmonologist — is where patients are lost. A network of 22,000 pharmacists, if it functions as a screening front line, is an attempt to close exactly that gap.
No funding details for the conference itself were disclosed in the reporting; the collaboration between a professional association and a commercial pharmacy chain is one readers should weigh when evaluating the five public health messages being promoted, which cover early recognition and response to exacerbations, proactive prevention, accessible medical knowledge, proper treatment for stable breathing, and long-term supportive care.
Seek urgent care for severe respiratory symptoms
Seek professional care urgently for breathlessness at rest, coughing up blood, chest pain, fever with worsening sputum, or symptoms that fail to respond to a prescribed reliever inhaler.
People with suspected COPD should never begin inhaled steroids or long-acting bronchodilators without a confirmed spirometry diagnosis, since asthma, heart failure and other conditions can mimic the disease and require different treatment. Smokers and former smokers over 40 with persistent cough or breathlessness should ask specifically for a lung function test.
The trajectory the conference set out is measured: earlier detection, steadier outpatient control, fewer emergency admissions. The next checkpoint is the December 4–6 regional meeting, where Vietnam’s community-care model will be tested against international scrutiny.
References
- vietnam.vn — Comprehensive COPD management conference report, November 15, 2026
- Ho Chi Minh City Association of Asthma, Allergy and Clinical Immunology — BPCO–ACOCU–PFT Day 2026 conference materials
- APAAACI 2026 — Asia-Pacific Association of Allergy, Asthma and Clinical Immunology annual congress program
Consult a qualified physician for diagnosis and treatment of any respiratory condition.